Ewa Antonina Biegańska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ewa Antonina Biegańska has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Marek Wolski
Department of Pediatric Surgery, Medical University of Warsaw, 02-091 Warsaw, Poland
3 shared publications - Przemyslaw Kosinski
Department of Obstetrics, Perinatology, Gynecology and Reproductive Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland
2 shared publications - Jakub Borkowski
Department of Pediatric Surgery, Medical University of Warsaw, Warsaw, Poland
1 shared publication - Jan Stachurski
Department of Emergency Medical Services, Faculty of Health Sciences, Medical University of Warsaw, Poland
1 shared publication - Jarosław Biliński
Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland
1 shared publication - Karol Rokicki
Student Research Association of Paediatric Emergency Medicine, Medical University of WarsawWarsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 9 March 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (3) , 437
Fecal Microbiota Transplantation (FMT) as a Prophylaxis of Necrotizing Enterocolitis (NEC)—Protocol for a Safety Study
Background/Objectives: Necrotizing enterocolitis (NEC) is an inflammatory disease with an incidence of about one in 1000 live births, much higher in premature and low birth weight newborns. Intestinal dysbiosis is an important element in the pathogenesis of NEC, and for this reason, experimental models have been used to administer fecal microbiota transplants (FMTs) for prophylaxis and treatment of NEC with very satisfactory results. The primary endpoint of the study is safety, defined as the incidence of adverse events (AEs) and serious adverse events (SAEs) occurring from the time of intervention until hospital discharge, classified according to severity and assessed for relatedness to the intervention. Methods: This prospective, single-arm, open-label clinical study will include 20 infants born between 24 0/7 and 36 6/7 weeks of gestation. FMTs will be administered twice as a deep rectal infusion via a Foley catheter. The donors of the material from which the FMT will be prepared will be women in the third trimester of pregnancy. The safety of the therapy will be assessed by comparison with a control group, i.e., 20 patients who will meet the same inclusion criteria and will not meet any of the exclusion criteria, subject to the same hospital observation but without undergoing any medical/therapeutic intervention other than the collection of biological material. Discussion: The study will provide data on the safety and initial efficacy of FMT in this group of patients, which will allow for further research into the use of this method in the prevention of infections and NEC. Ethics: The study protocol was approved by the Bioethics Committee of the Medical University of Warsaw, Warsaw, Poland (KB/52/2025). All procedures will follow the principles of the Declaration of Helsinki. The results of the study will be submitted for knowledge translation in peer-reviewed journals and presented at national and international pediatric society conferences. Clinical Trial Registration: The study is registered at ClinicalTrials.gov: ID: NCT06333405.
- 9 March 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (3) , 437
Open AccessFecal Microbiota Transplantation (FMT) as a Prophylaxis of Necrotizing Enterocolitis (NEC)—Protocol for a Safety Study
Background/Objectives: Necrotizing enterocolitis (NEC) is an inflammatory disease with an incidence of about one in 1000 live births, much higher in premature and low birth weight newborns. Intestinal dysbiosis is an important element in the pathogenesis of NEC, and for this reason, experimental models have been used to administer fecal microbiota transplants (FMTs) for prophylaxis and treatment of NEC with very satisfactory results. The primary endpoint of the study is safety, defined as the incidence of adverse events (AEs) and serious adverse events (SAEs) occurring from the time of intervention until hospital discharge, classified according to severity and assessed for relatedness to the intervention. Methods: This prospective, single-arm, open-label clinical study will include 20 infants born between 24 0/7 and 36 6/7 weeks of gestation. FMTs will be administered twice as a deep rectal infusion via a Foley catheter. The donors of the material from which the FMT will be prepared will be women in the third trimester of pregnancy. The safety of the therapy will be assessed by comparison with a control group, i.e., 20 patients who will meet the same inclusion criteria and will not meet any of the exclusion criteria, subject to the same hospital observation but without undergoing any medical/therapeutic intervention other than the collection of biological material. Discussion: The study will provide data on the safety and initial efficacy of FMT in this group of patients, which will allow for further research into the use of this method in the prevention of infections and NEC. Ethics: The study protocol was approved by the Bioethics Committee of the Medical University of Warsaw, Warsaw, Poland (KB/52/2025). All procedures will follow the principles of the Declaration of Helsinki. The results of the study will be submitted for knowledge translation in peer-reviewed journals and presented at national and international pediatric society conferences. Clinical Trial Registration: The study is registered at ClinicalTrials.gov: ID: NCT06333405.
- Open Access
- 24 January 2026
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 32, e949712
Predictors of Recurrence in Pediatric Perianal Abscess and Fistula-In-Ano: Insights From a 5-Year Surgical Cohort Study
Predictors of Recurrence in Pediatric Perianal Abscess and Fistula-In-Ano: Insights From a 5-Year Surgical Cohort Study - Article abstract #949712
- 24 January 2026
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 32, e949712
Open AccessPredictors of Recurrence in Pediatric Perianal Abscess and Fistula-In-Ano: Insights From a 5-Year Surgical Cohort Study
Predictors of Recurrence in Pediatric Perianal Abscess and Fistula-In-Ano: Insights From a 5-Year Surgical Cohort Study - Article abstract #949712
- Open Access
- 6 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1393
Possible Applications of Fecal Microbiota Transplantation in the Pediatric Population: A Systematic Review
Background: The potential therapeutic role of fecal microbiota transplantation (FMT) in various diseases has been thoroughly studied over the last few decades. However, the majority of studies focus on the adult population, therefore, conclusions regarding the application of FMT in the pediatric population are much less clear. This systematic review aims to summarize the research conducted so far on the efficacy and safety of FMT in the pediatric population, assess the quality of the evidence of its effectiveness, and outline the most promising areas for future research. Methods: We performed a systematic literature search from the index date to 8 June 2024 on the Embase, PubMed, and Web of Science databases. One author screened the resulting 121 articles. Eventually, 35 eligible studies that reported FMT use in seven different diseases were identified. Results: All of the studies assessed FMT as a safe procedure without many serious adverse effects. The best-documented application, which is the only one recommended in official guidelines, is recurrent Clostridioides difficile infection. Other disease entities in which the use of FMT has been studied with good clinical effects are inflammatory bowel disease, allergic colitis, autism, Tourette syndrome, and colonization with multi-drug-resistant organisms. However, it should be noted that the majority of studies are cohort and case-control studies, without randomization, which translates into low evidence quality. In one randomized, controlled trial focusing on the effect of FMT on weight loss in obese individuals, a lack of effect was found. Conclusions: While FMT and subsequent iterations of gut microbiota-targeted interventions hold promising therapeutic potential for various disease entities in the pediatric population, the current evidence behind this conclusion is of low quality. Based on current studies, these methods appear to be both effective and safe. However, further randomized clinical trials are necessary, especially within the pediatric population, for which such studies remain scarce.
- 6 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1393
Open AccessPossible Applications of Fecal Microbiota Transplantation in the Pediatric Population: A Systematic Review
Background: The potential therapeutic role of fecal microbiota transplantation (FMT) in various diseases has been thoroughly studied over the last few decades. However, the majority of studies focus on the adult population, therefore, conclusions regarding the application of FMT in the pediatric population are much less clear. This systematic review aims to summarize the research conducted so far on the efficacy and safety of FMT in the pediatric population, assess the quality of the evidence of its effectiveness, and outline the most promising areas for future research. Methods: We performed a systematic literature search from the index date to 8 June 2024 on the Embase, PubMed, and Web of Science databases. One author screened the resulting 121 articles. Eventually, 35 eligible studies that reported FMT use in seven different diseases were identified. Results: All of the studies assessed FMT as a safe procedure without many serious adverse effects. The best-documented application, which is the only one recommended in official guidelines, is recurrent Clostridioides difficile infection. Other disease entities in which the use of FMT has been studied with good clinical effects are inflammatory bowel disease, allergic colitis, autism, Tourette syndrome, and colonization with multi-drug-resistant organisms. However, it should be noted that the majority of studies are cohort and case-control studies, without randomization, which translates into low evidence quality. In one randomized, controlled trial focusing on the effect of FMT on weight loss in obese individuals, a lack of effect was found. Conclusions: While FMT and subsequent iterations of gut microbiota-targeted interventions hold promising therapeutic potential for various disease entities in the pediatric population, the current evidence behind this conclusion is of low quality. Based on current studies, these methods appear to be both effective and safe. However, further randomized clinical trials are necessary, especially within the pediatric population, for which such studies remain scarce.
- Open Access
- 9 February 2022
- Vol. 25 (3) , 236-242
Analysis of the patients hospitalised in paediatric trauma centers in Poland in 2019.
Paediatric trauma centers (PTCs) are facilities that were established to provide traumatised patients with fast, accurate diagnoses and optimal treatments. In Poland, they have been functioning since 2017. Our research aimed to assess the overall activity of the PTCs and cross-sectional data of their patients in Poland in 2019. We have analysed data provided by the National Health Fund (NHF) about the activity of seven trauma centers for children. For the PTC in the Paediatric Teaching Clinical Hospital University Clinical Center of the Medical University of Warsaw, we have gathered the data from the internal documentation system. In Poland, in 2019, there were seven operating PTCs. During that year, they hospitalised 195 severely traumatised patients. The available data have shown that no specialised tracking system of children admitted to PTCs was used; we have obtained data reporting final diagnoses, not the preliminary ones. Summarising the data from the PTC in Warsaw, in the first year of its operation there were 32 patients admitted, of which only 8 have met the criteria of admission. Due to the small number of patients reported, it is difficult to draw specific conclusions about the efficacy of PTCs in Poland. Obtaining reliable data is difficult, as there is no paediatric trauma patients database. To assess and improve the quality of PTCs, it would be profitable to create a national system monitoring the events and collecting data on the treatment results.
- 9 February 2022
- Vol. 25 (3) , 236-242
Open AccessAnalysis of the patients hospitalised in paediatric trauma centers in Poland in 2019.
Paediatric trauma centers (PTCs) are facilities that were established to provide traumatised patients with fast, accurate diagnoses and optimal treatments. In Poland, they have been functioning since 2017. Our research aimed to assess the overall activity of the PTCs and cross-sectional data of their patients in Poland in 2019. We have analysed data provided by the National Health Fund (NHF) about the activity of seven trauma centers for children. For the PTC in the Paediatric Teaching Clinical Hospital University Clinical Center of the Medical University of Warsaw, we have gathered the data from the internal documentation system. In Poland, in 2019, there were seven operating PTCs. During that year, they hospitalised 195 severely traumatised patients. The available data have shown that no specialised tracking system of children admitted to PTCs was used; we have obtained data reporting final diagnoses, not the preliminary ones. Summarising the data from the PTC in Warsaw, in the first year of its operation there were 32 patients admitted, of which only 8 have met the criteria of admission. Due to the small number of patients reported, it is difficult to draw specific conclusions about the efficacy of PTCs in Poland. Obtaining reliable data is difficult, as there is no paediatric trauma patients database. To assess and improve the quality of PTCs, it would be profitable to create a national system monitoring the events and collecting data on the treatment results.